Enzolytics Inc (ENZC)

[foxi]

Can you show proof of this statement, with links to references of this information?

So Samsung gave ENZC the boot?

We haven't seen much from Samsung after the PR last October. What conclusions can we draw other than for whatever reason they've chosen not to make additional announcements?

Under the terms of the agreement, Samsung Biologics will provide end-to-end
CDMO services from cell line development, clinical drug substance, and drug
product manufacturing services to support IND filings for Anti-HIV and
Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2.

In addition, there will be continuing discussions for other Monoclonal
Antibodies being developed by Enzolytics.

the 10/7 2021 PR

Master Service Agreement (“MDSA”) and Product Specific Agreement – Development and Manufacturing Services (”PSA”) entered into between Samsung Biologics Co., LTD. and Enzolytics, Inc. On October 7, 2021, the Company entered into a MDSA and PSA with Samsung Biologics Co., Ltd to advance the development of the Company’s human clone antibody program and clinical testing.

Quarterly Report for period 06.30.2022, page 12

So Samsung and ENZC really did partner. For some sort of compensation, Samsung acts as ENZC's CDMO for producing certain monoclonal antibodies. The initial agreements include a PSA which is for one product line. Probably Clone-3 mAbs per the "Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2" as noted in that Oct '21 PR.

Once produced, the monoclonal antibodies are tested for binding and neutralizing activity. These characteristics are confirmed by the Company's partnering laboratories, Genscript Labs, and the University of Strasbourg, France. After confirming antibody activity, the Company's CDMO partner Samsung Biologics produces recombinant antibodies in their proprietary, FDA-approved stable CHO cell line suitable for Clinical Application.

Quarterly Report for period 06.30.2022, page 17

So as of Q2 2022, Samsung has not 'given ENZC the boot'.

It's unclear whether the existing PSA covers the Class switched Clone 3 IgA1/IgA2 antibodies which maybe weren't discovered yet in October 2021 - but if the PSA is for Clone-3 anti Covid and anti HIV mAbs in general, it very well might.

We also have no information whether ENZC has entered into other PSAs with Samsung for other antibodies - but given that there's a MDSA and knowing "there will be continuing discussions for other Monoclonal Antibodies being developed by Enzolytics" then of course they could have.

This partnership with Abveris complements our efforts to significantly expand our antibody portfolio. We look forward to collaborating with Abveris to move us closer to our goal of expediently developing therapies for both human and veterinary use.

the 9/16 Abveris PR

Abveris self describes as "antibody enthusiasts discovering biologics for our partners against the most challenging classes of reagent and therapeutic targets, royalty-free!" (source)

Abveris combines its technologies with ENZC's AI platform to help ENZC hunt down candidate mAbs, which ENZC can then patent and enter new PSAs with Samsung or whoever to produce.

How is this not forward progress?

And if I missed something, I'd like to see links!




.